Hansa Biopharma is stepping up their portfolio and project management, choses Antura!

Hansa Biopharma, a pioneering company in biomedicine and pharmaceutical research, has opted to implement Antura as their solution for portfolio and project management. The goal is to gain a clearer project overview, optimize resource management, manage project finances, reduce reliance on manual processes in Excel and PowerPoint, and enable detailed project planning with clear timelines and deliveries.

Experiencing rapid growth, Hansa Biopharma has faced challenges associated with an expanding project portfolio and increasing resource needs. Traditionally relying on Excel and PowerPoint to manage projects, the company decided to acquire a project management tool. Following a competitive tender process, Hansa Biopharma selected Antura's project and portfolio system. The decision was based on criteria crucial to Hansa Biopharma, including:

  • Replacing existing tools like Excel and PowerPoint.

  • Managing project portfolios to collect project information, link them to strategies, and facilitate portfolio prioritization and simulation.

  • Enabling efficient resource management, including capacity planning, time reporting, and monitoring.

  • Streamlined project planning with support for various project models and the ability to track costs and results.

  • Integration possibilities with the company's existing financial systems.

Managing a diverse range of projects in the complex world of biomedicine and pharmaceutical research, Hansa Biopharma will now have a centralized platform for effective project overview with Antura. This will ease decision-making and resource allocation, providing a better overview of project budgets. By reducing dependence on manual processes, they aim to minimize the risk of errors and duplicate work.

Hansa Biopharma has chosen to implement Antura incrementally to adapt the project to their specific needs and requirements. 

Antura are grateful for the trust and looks forward to a long and fruitful collaboration. It will be exciting to follow Hansa Biopharma's progress as they develop and streamline their portfolio and project operations within their organization.

Hansa is a commercial-stage biopharmaceutical company and a pioneer in the development and commercialization of innovative, life-changing treatments for patients with rare immunological conditions. Founded in 2007 and headquartered in Lund, Sweden. The company also operates in other European countries and the United States. They were listed on Nasdaq First North Growth Market Stockholm from 2007 to 2015 and on Nasdaq Stockholm since 2015.